A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Inclusion Criteria:

1. Patients with newly diagnosed classical Hodgkin lymphoma (HL) confirmed byhistopathology;
2. Stage III-IV, or Stage IIB patients with at least one high-risk factor (NCCN standard)
3. Patients not suitable for receiving radiotherapy subsequently
4. Patients with at least one assessable lesion (according to Lugano 2014 standard);
5. Age 18 or above (including 18), no gender requirement;
6. ECOG PS score of 0-1 points;
7. Expected survival time ≥ 3 months;
8. Hematopoietic function: absolute neutrophil count ≥ 1.5×109/L, platelets ≥ 90×109/L,hemoglobin ≥ 90g/L; liver function: for patients with non-hepatitis B, totalbilirubin, ALT and AST <1.5×ULN (upper limit of normal); patients with hepatitis Bneed to take effective antiviral drugs, and HBV-DNA copy <2000 IU/ml and ALT<2×ULN;renal function: creatinine <1.5×ULN and creatinine clearance rate ≥50ml/min;
9. With normal main indicators of cardio-pulmonary function, and no obviouscontraindication to chemotherapy;
10. Not received any anti-tumor therapy such as radiotherapy, chemotherapy, targetedtherapy, cellular immunotherapy or hematopoietic stem cell transplantation beforeenrollment;
11. Voluntarily signing an informed consent form before trial screening.

Exclusion Criteria:

1. Nodular lymphocyte predominant HL;
2. Patients received any form of anti-tumor therapy in the past;
3. Patients planning to receive radiotherapy or autologous stem cell transplantation;
4. With involvement of central nervous system (meninges or brain parenchyma);
5. Pregnant and lactating women and child-bearing patients who are unwilling to takecontraceptive measures;
6. Patients with history of other tumors, except for cured cervical cancer orskin basalcell carcinoma; patients who have received organ transplantation;
7. Patients who have received symptomatic treatment of myelosuppressive toxicity within 7days before enrollment;
8. Patients who have used any immunosuppressive drugs within 4 weeks before thefirst-dose treatment,
9. Patients with known active interstitial pneumonia;
10. Abnormal liver function (total bilirubin>1.5×ULN, ALT/AST>2.5×ULN or ALT/AST>5×ULN forpatients with liver invasion), abnormal renal function (serum creatinine>1.5×ULN),abnormal electrolyte metabolism;
11. Peripheral neuropathy ≥ Grade 2;
12. Patients with a history of prolonged QT interval which is of clinical significance (male> 450ms, female> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF),heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF),patients with symptomatic coronary heart disease requiring drug therapy;
13. Patients with the end-diastolic width of fluid sonolucent area in pericardial cavity ≥10mm by cardiac B-ultrasonography;
14. Mentally disturbed/patients unable to give informed consent;
15. Patients who affect the evaluation of test results due to drug abuse or long-termalcohol abuse;
16. Participating in another interventional clinical study at the same time; Patients notsuitable to participate in this trial by the judgment of investigators.